Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Karici Diagnostics Inc. maintains a focused patent portfolio within the Biotechnology & Pharmaceuticals technology area. The company currently faces 1 pending office action, which represents the entirety of its active prosecution before the patent office. This matter is being handled within 1 distinct art unit, indicating a specialized or narrow scope for the pending application.
The prosecution is managed by 1 distinct examiner, YOUNG, MICAH PAUL. As the busiest examiner for the company, YOUNG, MICAH PAUL is responsible for 1 pending office action. This relationship between the company's pending workload and the examiner means that the progression of the Biotechnology & Pharmaceuticals portfolio depends entirely on the interactions with this specific official.
The presence of 1 distinct art unit and 1 distinct examiner shows a lack of diversification in current prosecution efforts. For Karici Diagnostics Inc., the primary focus remains on resolving the 1 pending office action to advance its intellectual property position in the biotechnology sector.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| YOUNG, MICAH PAUL | 1 | 55.1% | +30.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18612370 | CONTROLLED RELEASE FORMULATIONS FOR THE TREATMENT OF MALARIA | YOUNG, MICAH PAUL | 475d overdue |
| Art Unit | Apps |
|---|---|
| 1618 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18612370 | CONTROLLED RELEASE FORMULATIONS FOR THE TREATMENT OF MALARIA | YOUNG, MICAH PAUL | 1618 | §103 | Final Rejection | 475d overdue | Pending | Mar 21, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial